default author photo

Richard Rupp

University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences

TX

United States

SCHOLARLY PAPERS

3

DOWNLOADS

246

TOTAL CITATIONS

4

Scholarly Papers (3)

1.

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial

Number of pages: 40 Posted: 29 Dec 2021
Baylor College of Medicine, Harvard University - Brigham and Women’s Hospital, Meridian Clinical Research, Duke University - Duke Human Vaccine Institute, Government of the United States of America - Vaccine Research Center, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, Government of the United States of America - VA Greater Los Angeles Healthcare System (GLA), Rutgers, The State University of New Jersey - New Jersey Medical School, Lynn Health Science Institute (Lynn Institute), DM Clinical Research - Texas Center for Drug Development (TCDD), DM Clinical Research, Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc. and Independent
Downloads 127 (572,948)

Abstract:

Loading...

mRNA-1273, immunogenicity, antibodies, SARS-CoV-2, vaccine

2.

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant

Number of pages: 57 Posted: 08 Apr 2022
- Center for Vaccine Development and Global Health, Baylor College of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, - School of Medicine, Duke University - Duke Human Vaccine Institute, Kaiser Permanente Washington Health Research Institute, University of Rochester - Division of Infectious Diseases, Baylor College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, University of Pittsburgh - School of Medicine, University of Washington, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, New York University (NYU) - Grossman School of Medicine, University of Cincinnati - College of Medicine, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, New York University (NYU) - New York University Long Island School of Medicine, New York University (NYU) - Grossman School of Medicine, affiliation not provided to SSRN, University of Pittsburgh - School of Medicine, Emory University - School of Medicine, affiliation not provided to SSRN, Seattle Children’s Research Institute, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), affiliation not provided to SSRN, University of Washington - Vaccine and Infectious Disease Division, - Center for Vaccine Development and Global Health, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Emory University - Center for Childhood Infections and Vaccines, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Duke University - Duke Human Vaccine Institute and affiliation not provided to SSRN
Downloads 78 (830,555)
Citation 4

Abstract:

Loading...

COVID-19, SARS-CoV-2, Booster, Vaccine, Omicron variant, B.1.1.529, Neutralizing antibody, mRNA vaccine, recombinant adenovirus vaccine

3.

Pre-Existing Memory B Cell Phenotypes Determine the Quality of B Cell Response to Vaccine Boosters

Number of pages: 31 Posted: 24 Dec 2024
Government of the United States of America - Vaccine Research Center, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, - Center for Vaccine Development and Global Health, Baylor College of Medicine, - School of Medicine, Kaiser Permanente Washington Health Research Institute, University of Rochester - Division of Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, University of Pittsburgh - School of Medicine, University of Washington, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, New York University (NYU) - Grossman School of Medicine, University of Cincinnati - College of Medicine, New York University (NYU) - New York University Long Island School of Medicine, Emory University - School of Medicine, Independent, Fred Hutchinson Cancer Research Center, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Independent and Government of the United States of America - Vaccine Research Center
Downloads 41 (1,196,171)

Abstract:

Loading...

SARS-CoV-2 vaccine, prime-boost, B cell phenotype, atypical B cells, single-cell sequencing